AZD 1979

Drug Profile

AZD 1979

Alternative Names: AZD-1979

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Obesity therapies
  • Mechanism of Action Melanin-concentrating hormone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Obesity(In volunteers) in USA (PO, Liquid)
  • 28 Jul 2014 AstraZeneca terminates a phase I trial in healthy volunteers in USA after stopping criteria were reached (NCT02072993)
  • 31 Mar 2014 Phase-I clinical trials in Obesity (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top